AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15026873 — intervention group
Group type: COMPARATOR
Intervention: Single stenting
Number of subjects: 50
Study 15026873 — intervention group
Group type: EXPERIMENTAL
Intervention: Single stenting in type C lesions
Number of subjects: 50
Study 15026873 — intervention group
Group type: COMPARATOR
Intervention: Control group (diagnostic coronary angiography)
Number of subjects: 50
Study 11675056 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium supplementation (milk-extracted calcium phosphate)
Number of subjects: 116
Study 11675056 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 116
Study 10322830 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Sijunzi decoction (MSJZD)
Number of subjects: 202
Study 10322830 — intervention group
Group type: COMPARATOR
Intervention: Weimeisu
Number of subjects: 202
Study 8480058 — intervention group
Group type: EXPERIMENTAL
Intervention: Active group (nicotine chewing gum + group psychotherapy)
Number of subjects: 106
Study 8480058 — intervention group
Group type: COMPARATOR
Intervention: Placebo group (placebo chewing gum + group psychotherapy)
Number of subjects: 106
Study 8480058 — intervention group
Group type: EXPERIMENTAL
Intervention: Outpatient group (nicotine chewing gum + individual psychotherapy)
Number of subjects: 106
Study 3039234 — intervention group
Group type: EXPERIMENTAL
Intervention: Low NaCl Group (2 to 7 mEq/day)
Number of subjects: 6
Study 3039234 — intervention group
Group type: COMPARATOR
Intervention: High NaCl Group (126 mEq/day)
Number of subjects: 6
Study 30953176 — intervention group
Group type: EXPERIMENTAL
Intervention: Ischemic preconditioning (IPC) protocol (5 min ischemia, repeated 3 times, each separated by 5 min reperfusion) before every training session
Number of subjects: 14
Study 30953176 — intervention group
Group type: COMPARATOR
Intervention: Control group (identical endurance training without IPC)
Number of subjects: 14
Study 27494634 — intervention group
Group type: EXPERIMENTAL
Intervention: School Asthma Action Program (SAAP)
Number of subjects: 47
Study 25609231 — intervention group
Group type: EXPERIMENTAL
Intervention: DAIRY (1% fat milk, 1.5% fat yogurt, 34% fat cheese)
Number of subjects: 124
Study 25609231 — intervention group
Group type: COMPARATOR
Intervention: CONTROL (fruit and vegetable juice, cashews, and a cookie)
Number of subjects: 124
Study 23432730 — intervention group
Group type: EXPERIMENTAL
Intervention: Brinzolamide-timolol fixed combination
Number of subjects: 92
Study 23432730 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 92
Study 21115134 — intervention group
Group type: COMPARATOR
Intervention: GoLytely (4 L split-dose)
Number of subjects: 403
Study 21115134 — intervention group
Group type: EXPERIMENTAL
Intervention: MiraLAX alone (combined with 64 oz of Gatorade)
Number of subjects: 403
Study 21115134 — intervention group
Group type: EXPERIMENTAL
Intervention: MiraLAX with lubiprostone (24 μg)
Number of subjects: 403
Study 21115134 — intervention group
Group type: EXPERIMENTAL
Intervention: MiraLAX with bisacodyl (10 mg)
Number of subjects: 403
Study 21115134 — intervention group
Group type: EXPERIMENTAL
Intervention: MiraLAX (all groups)
Number of subjects: 403
Study 21115134 — intervention group
Group type: EXPERIMENTAL
Intervention: GoLytely and MiraLAX groups
Number of subjects: 403
Study 18932058 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination treatment with 500 mg alpha‐tocopherol and 2 g vitamin C for 12 weeks
Number of subjects: 14
Study 18932058 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 16676013 — intervention group
Group type: EXPERIMENTAL
Intervention: Mailed orientation program (intervention)
Number of subjects: 0
Study 16676013 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 12836023 — intervention group
Group type: EXPERIMENTAL
Intervention: Associative group with predictable damping force based on initial position
Number of subjects: 32
Study 12836023 — intervention group
Group type: COMPARATOR
Intervention: Non-associative group with unpredictable damping force
Number of subjects: 32
Study 11342473 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 g/kg IVIG
Number of subjects: 62
Study 11342473 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study 8803738 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic prophylaxis
Number of subjects: 600
Study 8803738 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 600
Study 1411634 — intervention group
Group type: COMPARATOR
Intervention: Combination cisplatin and carboplatin plus doxorubicin/hexamethylmelamine/cyclophosphamide
Number of subjects: 341
Study 1411634 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous carboplatin (350 mg/m2 on day 1) plus oral cyclophosphamide (100 mg/m2 days 2 to 6)
Number of subjects: 341
Study 1411634 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose carboplatin (800 mg/m2)
Number of subjects: 341
Study 3880635 — intervention group
Group type: EXPERIMENTAL
Intervention: Cephradine
Number of subjects: 50
Study 3880635 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 30652892 — intervention group
Group type: COMPARATOR
Intervention: Interacting pairs in a visual search task (Experiments 1a and 1b)
Number of subjects: 0
Study 30652892 — intervention group
Group type: COMPARATOR
Intervention: Interacting individuals in a spatial judgment task (Experiments 2a and 2b)
Number of subjects: 0
Study 30652892 — intervention group
Group type: COMPARATOR
Intervention: Interacting partners in a surprise memory task (Experiments 3a and 3b)
Number of subjects: 0
Study 28553750 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based intervention (Let's Choose Ourselves)
Number of subjects: 0
Study 28553750 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 26951379 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab (10 mg/kg every 2 weeks)
Number of subjects: 91
Study 26951379 — intervention group
Group type: EXPERIMENTAL
Intervention: Fotemustine (75 mg/m² on days 1, 8, and 15, then 100 mg/m² every 3 weeks after a 35-day interval)
Number of subjects: 91
Study 24702886 — intervention group
Group type: EXPERIMENTAL
Intervention: mannitol
Number of subjects: 20
Study 24702886 — intervention group
Group type: COMPARATOR
Intervention: deep inhalation methacholine challenge
Number of subjects: 20
Study 22999372 — intervention group
Group type: EXPERIMENTAL
Intervention: High-viscosity glass-ionomer (Fuji IX GP(®))
Number of subjects: 35
Study 22999372 — intervention group
Group type: EXPERIMENTAL
Intervention: Resin-modified glass-ionomer (Vitremer(®))
Number of subjects: 35
Study 22999372 — intervention group
Group type: COMPARATOR
Intervention: Control (Sound teeth)
Number of subjects: 35
Study 20703472 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrasphincteric injection of botulinum toxin (BT)
Number of subjects: 80
Study 20703472 — intervention group
Group type: COMPARATOR
Intervention: Lateral internal sphincterotomy (LIS)
Number of subjects: 80
Study 19017911 — intervention group
Group type: EXPERIMENTAL
Intervention: G. biloba (120 mg twice daily)
Number of subjects: 3069
Study 19017911 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3069
Study 16018146 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal 17 beta‐estradiol 300 microg daily
Number of subjects: 309
Study 12144817 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV testing
Number of subjects: 314
Study 12144817 — intervention group
Group type: COMPARATOR
Intervention: Cytology
Number of subjects: 314
Study 10638109 — intervention group
Group type: EXPERIMENTAL
Intervention: nimesulide
Number of subjects: 90
Study 10638109 — intervention group
Group type: COMPARATOR
Intervention: piroxicam
Number of subjects: 90
Study 7804897 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemopreventive agents
Number of subjects: 0
Study 1553935 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam (0.25 mg, three times a day)
Number of subjects: 10
Study 1553935 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 3159407 — intervention group
Group type: EXPERIMENTAL
Intervention: diazepam 0.2 mg kg‐1 i.v.
Number of subjects: 76
Study 3159407 — intervention group
Group type: EXPERIMENTAL
Intervention: midazolam 0.05 mg kg‐1 i.v.
Number of subjects: 76
Study 3159407 — intervention group
Group type: EXPERIMENTAL
Intervention: midazolam 0.1 mg kg‐1 i.v.
Number of subjects: 76
Study 29198539 — intervention group
Group type: EXPERIMENTAL
Intervention: Tight glycemic control
Number of subjects: 88
Study 29198539 — intervention group
Group type: COMPARATOR
Intervention: Standard glycemic control
Number of subjects: 88
Study 26152668 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted cognitive training (N = 18) for 50 hours
Number of subjects: 34
Study 26152668 — intervention group
Group type: COMPARATOR
Intervention: Computer games control (N = 16)
Number of subjects: 34
Study 23448285 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioural treatment (pelvic floor muscle training, delayed voiding, urge suppression techniques)
Number of subjects: 127
Study 23448285 — intervention group
Group type: COMPARATOR
Intervention: Antimuscarinic drug therapy (extended-release oxybutynin)
Number of subjects: 127
Study 23448285 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioural treatment (for those with ≥2 episodes nocturia at baseline)
Number of subjects: 127
Study 23448285 — intervention group
Group type: COMPARATOR
Intervention: Antimuscarinic therapy (for those with ≥2 episodes nocturia at baseline)
Number of subjects: 127
Study 21070382 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct ball attachment incorporation (group A)
Number of subjects: 45
Study 21070382 — intervention group
Group type: COMPARATOR
Intervention: Indirect ball attachment incorporation (group B)
Number of subjects: 45
Study 18799365 — intervention group
Group type: EXPERIMENTAL
Intervention: Cystatin C (CysC)
Number of subjects: 38
Study 18799365 — intervention group
Group type: COMPARATOR
Intervention: aMDRD
Number of subjects: 38
Study 18799365 — intervention group
Group type: COMPARATOR
Intervention: C&G
Number of subjects: 38
Study 17304525 — intervention group
Group type: EXPERIMENTAL
Intervention: Burch urethropexy
Number of subjects: 390
Study 17304525 — intervention group
Group type: EXPERIMENTAL
Intervention: Fascial sling
Number of subjects: 390
Study 15490824 — intervention group
Group type: EXPERIMENTAL
Intervention: Bicoherence analysis using statistical tools for thresholding
Number of subjects: 0
Study 11677204 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotics (20 mg omeprazole, 250 mg clarithromycin, and 500 mg tinidazole twice a day for 1 week)
Number of subjects: 190
Study 11677204 — intervention group
Group type: COMPARATOR
Intervention: Placebo (20 mg omeprazole twice a day and identical placebos for 1 week)
Number of subjects: 190
Study 11677204 — intervention group
Group type: COMPARATOR
Intervention: H. pylori-negative group (open label 20 mg omeprazole twice a day for 1 week)
Number of subjects: 190
Study 9058440 — intervention group
Group type: EXPERIMENTAL
Intervention: Total Parenteral Nutrition (TPN)
Number of subjects: 12
Study 9058440 — intervention group
Group type: COMPARATOR
Intervention: Oral diet
Number of subjects: 12
Study 8445307 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefotaxime sodium for 24 hours
Number of subjects: 60
Study 8445307 — intervention group
Group type: COMPARATOR
Intervention: Cefotaxime sodium for 7 days
Number of subjects: 60
Study 3007163 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol 80 mg b.i.d.
Number of subjects: 10
Study 3007163 — intervention group
Group type: COMPARATOR
Intervention: Metoprolol 100 mg b.i.d.
Number of subjects: 10
Study 29912844 — intervention group
Group type: EXPERIMENTAL
Intervention: Booster dose of IXIARO administered 12 months after primary immunization
Number of subjects: 300
Study 29912844 — intervention group
Group type: COMPARATOR
Intervention: No booster dose
Number of subjects: 300
Study 29912844 — intervention group
Group type: EXPERIMENTAL
Intervention: Booster dose of IXIARO
Number of subjects: 300
Study 26315004 — intervention group
Group type: EXPERIMENTAL
Intervention: Valve setting reduced from 20 cm H2O to 4 cm H2O over 6 months (20-4 group)
Number of subjects: 68
Study 26315004 — intervention group
Group type: COMPARATOR
Intervention: Fixed valve setting at 12 cm H2O (12 group)
Number of subjects: 68
Study 24627290 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemigliptin (50 mg once daily) and Metformin (1,000 mg twice a day)
Number of subjects: 27
Study 24627290 — intervention group
Group type: COMPARATOR
Intervention: Metformin (1,000 mg twice a day)
Number of subjects: 27
Study 22278162 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical therapy (hot pack, ultrasound therapy, friction massage)
Number of subjects: 59
Study 22278162 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroid injection
Number of subjects: 59
Study 22278162 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal shock wave treatment (ESWT)
Number of subjects: 59
Study 22278162 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 59
Study 20357382 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranolazine
Number of subjects: 171
Study 20357382 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 171
Study 18771887 — intervention group
Group type: EXPERIMENTAL
Intervention: TAG endograft
Number of subjects: 234
Study 18771887 — intervention group
Group type: COMPARATOR
Intervention: Open surgery
Number of subjects: 234
Study 18771887 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined morbidity/mortality endpoint (stroke/paralysis/MI/death)
Number of subjects: 234
Study 18771887 — intervention group
Group type: EXPERIMENTAL
Intervention: TAG
Number of subjects: 234
Study 18771887 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular group
Number of subjects: 234
Study 18771887 — intervention group
Group type: EXPERIMENTAL
Intervention: Procedure times
Number of subjects: 234
Study 16364831 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin
Number of subjects: 284
Study 16364831 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 284
Study 12456445 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol infusion (1 mg/kg loading dose, 0.2 mg/kg/h postoperative infusion)
Number of subjects: 69
Study 12456445 — intervention group
Group type: COMPARATOR
Intervention: Morphine PCA alone (control group)
Number of subjects: 69
Study 10333097 — intervention group
Group type: EXPERIMENTAL
Intervention: Treadmill
Number of subjects: 32
Study 10333097 — intervention group
Group type: COMPARATOR
Intervention: Cycle Ergometer
Number of subjects: 32
Study 10333097 — intervention group
Group type: EXPERIMENTAL
Intervention: Both Treadmill and Cycle Ergometer
Number of subjects: 32
Study 8619358 — intervention group
Group type: EXPERIMENTAL
Intervention: Iobitridol (Xenetix 350)
Number of subjects: 90
Study 8619358 — intervention group
Group type: COMPARATOR
Intervention: Iohexol (Omnipaque)
Number of subjects: 90
Study 2031819 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. atropine 0.5 mg
Number of subjects: 90
Study 2031819 — intervention group
Group type: COMPARATOR
Intervention: i.v. saline 1 ml
Number of subjects: 90
Study 2031819 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. lignocaine 3 ml with adrenaline 15 micrograms
Number of subjects: 90
Study 2031819 — intervention group
Group type: EXPERIMENTAL
Intervention: adrenaline test dose
Number of subjects: 90
Study 7404171 — intervention group
Group type: EXPERIMENTAL
Intervention: Alveolar lavage
Number of subjects: 0
Study 7404171 — intervention group
Group type: EXPERIMENTAL
Intervention: Transbronchial biopsy
Number of subjects: 0
Study 7404171 — intervention group
Group type: EXPERIMENTAL
Intervention: Graded radiological evaluation
Number of subjects: 0
Study 7404171 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of transbronchial biopsy, alveolar lavage, and radiography
Number of subjects: 0
Study 31980506 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc acetate lozenges (13 mg elemental zinc, taken six times per day for a maximum of 5 days)
Number of subjects: 253
Study 31980506 — intervention group
Group type: COMPARATOR
Intervention: Placebo lozenges (sucrose octa-acetate, taken six times per day for a maximum of 5 days)
Number of subjects: 253
Study 31484629 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 11154
Study 31484629 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11154
Study 28628688 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser treatment and nutraceutical (Group 2)
Number of subjects: 20
Study 28628688 — intervention group
Group type: COMPARATOR
Intervention: Laser treatment (Group 1)
Number of subjects: 20
Study 25940727 — intervention group
Group type: EXPERIMENTAL
Intervention: Aggressive suction‐curettage
Number of subjects: 130
Study 25940727 — intervention group
Group type: COMPARATOR
Intervention: Open excision
Number of subjects: 130
Study 23393307 — intervention group
Group type: EXPERIMENTAL
Intervention: Innovative curriculum using trigger videos modeling screening for SDH
Number of subjects: 36
Study 23393307 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly detailed)
Number of subjects: 36
Study 21324965 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient Global Assessment (PGA) using a 0-100 mm visual analog scale (VAS)
Number of subjects: 319
Study 21324965 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient Joint Assessment (PJA) using a 0-100 mm VAS
Number of subjects: 319
Study 21324965 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient Skin Assessment (PSA) using a 0-100 mm VAS
Number of subjects: 319
Study 21324965 — intervention group
Group type: EXPERIMENTAL
Intervention: PGA scores
Number of subjects: 319
Study 21324965 — intervention group
Group type: EXPERIMENTAL
Intervention: PJA scores
Number of subjects: 319
Study 21324965 — intervention group
Group type: EXPERIMENTAL
Intervention: PSA scores
Number of subjects: 319
Study 21324965 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between joint and skin disease activity
Number of subjects: 319
Study 19363239 — intervention group
Group type: EXPERIMENTAL
Intervention: Haemorheopheresis (separator Cobe.Spetra + Evaflux filter)
Number of subjects: 24
Study 17531926 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated BP group
Number of subjects: 66
Study 15690714 — intervention group
Group type: EXPERIMENTAL
Intervention: Helicobacter pylori eradication therapy; specific dosage and duration not mentioned.
Number of subjects: 0
Study 15690714 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo); specific details not mentioned.
Number of subjects: 0
Study 11684821 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-tissue transglutaminase (tTG) test
Number of subjects: 258
Study 11684821 — intervention group
Group type: COMPARATOR
Intervention: Control group of 180 healthy donors without hypertransaminasemia
Number of subjects: 258
Study 11684821 — intervention group
Group type: COMPARATOR
Intervention: Control group of 20 CD patients known to be EmA positive
Number of subjects: 258
Study 11684821 — intervention group
Group type: EXPERIMENTAL
Intervention: Biopsy of distal duodenal mucosa
Number of subjects: 258
Study 11684821 — intervention group
Group type: EXPERIMENTAL
Intervention: Gluten-free diet
Number of subjects: 258
Study 10518866 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate dentifrices (45% NaHCO3)
Number of subjects: 12
Study 10518866 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate dentifrices (65% NaHCO3)
Number of subjects: 12
Study 10518866 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate dentifrices (94% NaHCO3)
Number of subjects: 12
Study 10518866 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate dentifrices (94% NaHCO3 + 1.5% H2O2)
Number of subjects: 12
Study 10518866 — intervention group
Group type: COMPARATOR
Intervention: Control (distilled water)
Number of subjects: 12
Study 10518866 — intervention group
Group type: COMPARATOR
Intervention: Silica dentifrice (Crest Regular Toothpaste)
Number of subjects: 12
Study 10518866 — intervention group
Group type: COMPARATOR
Intervention: Dicalcium phosphate dentifrice (Colgate Regular Toothpaste)
Number of subjects: 12
Study 8083147 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH) 5 mg, 10 mg, 15 mg
Number of subjects: 40
Study 8083147 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 2792618 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group (n = 50) - received detailed information and extensive physical examination
Number of subjects: 100
Study 2792618 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 50) - received standard care
Number of subjects: 100
Study 956343 — intervention group
Group type: EXPERIMENTAL
Intervention: Meclastine (oral administration for three days)
Number of subjects: 30
Study 956343 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexchlorpheniramine (intravenous infusion)
Number of subjects: 30
Study 956343 — intervention group
Group type: COMPARATOR
Intervention: Insulin hypoglycemia
Number of subjects: 30
Study 31612597 — intervention group
Group type: EXPERIMENTAL
Intervention: Acotiamide
Number of subjects: 16
Study 31612597 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 30655639 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic and dietetic intervention to correct hypotension until SBP > 100 mmHg
Number of subjects: 54
Study 28522450 — intervention group
Group type: EXPERIMENTAL
Intervention: SGLT-2i
Number of subjects: 309056
Study 28522450 — intervention group
Group type: COMPARATOR
Intervention: Other glucose-lowering drugs
Number of subjects: 309056
Study 25614164 — intervention group
Group type: EXPERIMENTAL
Intervention: Riociguat, individually adjusted up to a maximum dose of 2.5 mg three times daily
Number of subjects: 396
Study 24287218 — intervention group
Group type: EXPERIMENTAL
Intervention: Arm stretch positioning combined with motor amplitude NMES for two 45‐minute sessions a day, five days a week, for eight weeks
Number of subjects: 46
Study 24287218 — intervention group
Group type: COMPARATOR
Intervention: Sham arm positioning and sham NMES (transcutaneous electrical nerve stimulation with no motor effect) to the forearm only, at a similar frequency and duration
Number of subjects: 46
Study 21142844 — intervention group
Group type: EXPERIMENTAL
Intervention: Nucleoside and protease inhibitor antiretroviral therapy (ARV) during first trimester
Number of subjects: 1414